Figure 1
![Figure 1. JAK2 is present in both the cytoplasm and the nucleoplasm. (A) Subcellular fractionation was performed in Ba/F3 EPO-R and TF-1 cell lines stably expressing a JAK2V617F EGFP fusion construct and subcellular distribution was assessed by immunoblotting. Endogenous JAK2 and JAK2 GFP Fusion protein were present in both the cytoplasm [C] and the nucleoplasm [N]. α-tubulin was used as a cytoplasmic marker. (B) JAK2 compartmentalizes to both the nuclear and cytoplasmic fractions in fractionation experiments in a panel of leukemic cell lines expressing endogenous JAK2V617F mutation (SET2, UKE1, and HEL).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/26/10.1182_blood-2011-10-385278/4/zh89991183720001.jpeg?Expires=1735801820&Signature=dQznqXl9WYsL5QGvxV7Ymz271RuIS0S39ra-2sfU0CtrdB7GAuDjc6w6PBJqS7WgVkPh1BIHt8yXo-Yqv-fOPrIywXZ32Dvt1c35rsTtqlkNgtrbzw~AIFWrowdL40ZWlD5~iRPJ8EKrAWI72KJskrlLcL9bo~amD6O-t-PQsWfTdtGVcotz7j1A1vI35gUuRbBDOs3sFFlkOpQmneS-miyo4CXpMCxYWbc3BJ4jpmK01MVYcf-JAUV5SikPHTqb4AkhrYVWbD-pGY13VZ48eDgBbjGEAyTnL4IuZBACHo2buuiebMRPN5B~oNIw3XYfLDsnX-~S-2VCn2u3Q8Keww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
JAK2 is present in both the cytoplasm and the nucleoplasm. (A) Subcellular fractionation was performed in Ba/F3 EPO-R and TF-1 cell lines stably expressing a JAK2V617F EGFP fusion construct and subcellular distribution was assessed by immunoblotting. Endogenous JAK2 and JAK2 GFP Fusion protein were present in both the cytoplasm [C] and the nucleoplasm [N]. α-tubulin was used as a cytoplasmic marker. (B) JAK2 compartmentalizes to both the nuclear and cytoplasmic fractions in fractionation experiments in a panel of leukemic cell lines expressing endogenous JAK2V617F mutation (SET2, UKE1, and HEL).
